Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRC-101 in Advanced Solid Malignancies
NCT04244552Phase 1Terminated
- Sponsor
- Atreca, Inc.
- Start
- Feb 2020
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATRC-101 in breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 10 more (4 arms), sponsored by Atreca, Inc. Primary endpoint: Incidence of DLTs, treatment emergent adverse events (TEAEs), and changes in safety parameters at 24 months. Started Feb 2020; status: terminated.
02
Drugs
ATRC-101
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)colorectal cancer (CRC)ovarian canceracral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT04244552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244552.